Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Introduction
2.2 Scope of the Study
2.3 Assumptions & Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing Healthcare Expenditure
4.2.2 Advancements in Biologics
4.2.3 Rising Prevalence of Chronic and Acute Diseases
4.3 Restraints
4.3.1 Emergence of Biosimilars
4.3.2 Adverse Effects of Biologic Drugs
4.4 Opportunities
4.4.1 Strong Pipeline for Biologic Drugs
5 Market Factor Analysis
5.1 Value/Supply Chain Analysis
5.1.1 Research & Development
5.1.2 Raw Material
5.1.3 Manufacturer
5.1.4 Distributor
5.1.5 Customer
5.1.6 Consumer
5.2 Porter's Five Force Analysis
5.2.1 Threat from a New Entrant
5.2.2 Bargaining Power of Buyer
5.2.3 Bargaining Power of Supplier
5.2.4 Threat from Substitute
5.2.5 Rivalry
5.3 Investment Opportunity Analysis
5.3.1 Investment Risks
5.3.2 Market Outlook
5.4 Pricing Analysis
6 Global Biologics Market, by Product
6.1 Overview
6.2 Monoclonal Antibody
6.2.1 Humanized
6.2.2 Human
6.2.3 Chimeric
6.2.4 Murine
6.3 Interleukins
6.4 Vaccines
6.5 Growth Factors
6.6 Gene Therapy
7 Global Biologics Market, by Disease Indication
7.1 Overview
7.2 Cancer
7.3 Rheumatoid Arthritis
7.4 Psoriasis/ Psoriatic Arthritis
7.5 Diabetes
7.6 Ankylosing Spondylitis
7.7 Ulcerative Colitis
7.8 Crohn's Disease
7.9 Juvenile Idiopathic Arthropathy
7.1 Cardiovascular Diseases
8 Global Biologics Market, by Manufacturing
8.1 Overview
8.2 In-house
8.3 Outsourced
?
9 Global Biologics Market, by Region
9.1 Overview
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 UK
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
10 Competitive Landscape
10.1 Company Market Share Analysis
10.2 Competitive Scenario
11 Company Profiles
11.1 AbbVie, Inc.
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products/Services Offering
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategy
11.2 Pfizer Inc.
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products/Services Offering
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategy
11.3 AstraZeneca
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products/Services Offering
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategy
11.4 Novartis AG
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products Offering
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategy
11.5 F. Hoffmann-La Roche AG
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products Offering
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategy
11.6 Bayer AG
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products Offering
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategy
11.7 Amgen
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products Offering
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategy
11.8 Sanofi
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products Offering
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategy
11.9 Eli Lilly and Company
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products Offering
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategy
11.1 GlaxoSmithKline Plc (GSK)
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products Offering
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategy
12 Appendix
12.1 Discussion Blue Print